MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
28.87
-0.17 (-0.59%)
Apr 29, 2026, 11:13 AM EDT - Market open
MBX Biosciences Employees
MBX Biosciences had 63 employees as of December 31, 2025. The number of employees increased by 20 or 46.51% compared to the previous year.
Employees
63
Change (1Y)
20
Growth (1Y)
46.51%
Revenue / Employee
n/a
Profits / Employee
-$1,380,492
Market Cap
1.37B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63 | 20 | 46.51% |
| Dec 31, 2024 | 43 | 16 | 59.26% |
| Dec 31, 2023 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Immatics | 711 |
| Agios Pharmaceuticals | 540 |
| Immunocore Holdings | 524 |
| Ardelyx | 489 |
| Biohaven | 274 |
| Precigen | 160 |
| Bicara Therapeutics | 103 |
MBX News
- 6 days ago - MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio - GlobeNewsWire
- 26 days ago - MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 6 weeks ago - MBX Biosciences Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - MBX Biosciences Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 7 weeks ago - MBX Biosciences Appoints Karen Basbaum as Chief Business Officer - GlobeNewsWire
- 7 weeks ago - CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism - GlobeNewsWire
- 7 weeks ago - MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism - GlobeNewsWire